Can COVID-19 pandemic boost the epidemic of neurodegenerative diseases?
Alexei VerkhratskyQing LiSonia MelinoGerry MelinoYufang ShiPublished in: Biology direct (2020)
The pandemic of Coronavirus Disease 2019 (COVID-19) presents the world with the medical challenge associated with multifactorial nature of this pathology. Indeed COVID-19 affects several organs and systems and presents diversified clinical picture. COVID-19 affects the brain in many ways including direct infection of neural cells with SARS-CoV-2, severe systemic inflammation which floods the brain with pro-inflammatory agents thus damaging nervous cells, global brain ischaemia linked to a respiratory failure, thromboembolic strokes related to increased intravascular clotting and severe psychological stress. Often the COVID-19 is manifested by neurological and neuropsychiatric symptoms that include dizziness, disturbed sleep, cognitive deficits, delirium, hallucinations and depression. All these indicate the damage to the nervous tissue which may substantially increase the incidence of neurodegenerative diseases and promote dementia.
Keyphrases
- coronavirus disease
- sars cov
- respiratory syndrome coronavirus
- induced apoptosis
- sleep quality
- respiratory failure
- cell cycle arrest
- white matter
- resting state
- cerebral ischemia
- early onset
- extracorporeal membrane oxygenation
- healthcare
- depressive symptoms
- physical activity
- risk factors
- multiple sclerosis
- oxidative stress
- cell death
- mechanical ventilation
- atrial fibrillation
- cardiac surgery
- drug induced
- subarachnoid hemorrhage
- hip fracture